Introduction
============

Molecular cytogenetic techniques such as array-based comparative genomic hybridization (aCGH) have revolutionized cytogenetic diagnostics and, in turn, the clinical management of patients with developmental delays and multiple congenital anomalies \[[@B1],[@B2]\]. These rapid, high-resolution, and highly accurate techniques have identified numerous previously unrecognized chromosomal syndromes \[[@B3]-[@B8]\], refined critical regions for established genetic defects \[[@B9]\], and broadened our view of the \"normal\" diploid genome \[[@B10]\]. In addition, aCGH has given the clinician a greater appreciation of variability in the clinical presentation of many well-described conditions \[[@B11],[@B12]\] and allowed for the discovery of new conditions with relatively mild phenotypes \[[@B13],[@B14]\]. Furthermore, the application of aCGH has created a paradigm shift in genetics that has moved the description and discovery of genetic conditions from the \"phenotype-first\" approach, in which patients exhibiting similar clinical features are identified prior to the discovery of an underlying etiology, to a \"genotype-first\" approach, in which a collection of individuals with similar copy-number imbalances can be examined for common clinical features \[[@B15]\].

Originally, targeted microarrays constructed from bacterial artificial chromosomes (BAC) were developed for the clinical laboratory because of their ability to clearly identify copy number changes in discrete regions of the human genome known to play a role in genetic disease \[[@B16]\]. This \"less is more\" idea prevailed in the early years of clinical aCGH because the technology was new and proof of principle was required before it could be adopted for more widespread diagnostic use. Furthermore, the identification of copy number alterations of unclear clinical significance was considered undesirable to the diagnostician, the ordering physician, and the patient\'s family. Recently, the coverage of microarrays has expanded to include more comprehensive coverage of the human genome, leading many to suggest that whole-genome BAC or oligo arrays are the next step in the continued improvement in the detection rate of cytogenetic abnormalities.

It has been presumed that whole-genome oligonucleotide arrays, because they have higher resolutions, would detect more copy number aberrations than whole-genome BAC arrays. However, to our knowledge, there has not been a systematic comparison of these two whole-genome copy number screening technologies in a clinical diagnostic environment. Therefore, to determine which platform is most effective in identifying clinically significant DNA copy number alterations, we designed a whole-genome BAC array and a whole-genome oligo array and compared the results in a blinded study of 466 clinical diagnostic specimens. In addition, we prospectively evaluated 3,443 patients by the whole-genome BAC array and 3,096 patients by the whole-genome oligo array and compared the detection rates of clinically significant abnormalities and those of unclear clinical significance. Finally, we validated our oligo array with 48 cases to determine the level of mosaicism that can be reliably detected and compared that level to our previously published cases analyzed using the BAC array.

Materials and methods
=====================

Whole-genome BAC array design and aCGH
--------------------------------------

We constructed a whole-genome BAC array designed for clinical diagnostic use using \>4,600 BAC clones. All clones were validated by FISH prior to inclusion on the array using previously described validation procedures \[[@B16]\]. Contigs of 3-6 overlapping clones were selected to cover 1,543 genetic loci, including \>150 known microdeletion/microduplication syndromes and increased density of coverage in the 5-10 Mb surrounding the subtelomeric and pericentromeric regions of the genome. In addition, we placed contigs to cover \>500 functionally significant genes such as transcription factors and other genes known to play important roles in development. This coverage also includes genome-wide representation with at least one contig in nearly every chromosomal band at the resolution of an 850-band karyotype. The mean gap size for the whole-genome BAC array is \~1.6 Mb. Microarray manufacturing and aCGH analysis using the whole-genome BAC array were performed as previously described \[[@B13]\]. BAC arrays were analyzed after a dye-swap, two-experiment analysis \[[@B16]\], using sex-mismatched controls. Results were then displayed using custom BAC aCGH analysis software (Genoglyphix™; Signature Genomic Laboratories, Spokane, WA).

Whole-genome Oligonucleotide Array Design and aCGH
--------------------------------------------------

Oligonucleotide-based microarray analysis was performed using a custom-designed, 105K-feature whole-genome microarray manufactured by Agilent Technologies (Santa Clara, CA) with one probe every 10 kb in regions of interest\--microdeletion/microduplication syndromes, the pericentromeric regions, subtelomeres and genes involved in important developmental pathways\--for an average of 50 oligos per clinical locus. In addition, to achieve backbone coverage, we placed a probe, on average, every 35 kb throughout the rest of the genome between the regions of interest. Genomic DNA labeling was performed as described for BAC arrays, whereas array hybridization and washing were performed as specified by the manufacturer (Agilent Technologies). A dye swap was not performed for the oligo arrays, and sex-matched controls were used. Arrays were scanned and analyzed as previously described \[[@B17]\]. Results of aberration calls consisting of five or more consecutive oligos were then displayed using custom oligonucleotide aCGH analysis software (Genoglyphix™; Signature Genomic Laboratories). The use of five consecutive oligos achieved a resolution of 40 kb in the regions of interest and a resolution of 140 kb in the backbone.

Decision Algorithm for Clinically Significant Copy Number Reporting
-------------------------------------------------------------------

We developed a decision algorithm for classifying clinically significant copy number alterations, alterations of unclear clinical significance, and alterations of no currently known clinical significance. Alterations that were associated with established chromosomal syndromes, were large and affected a significant amount of gene content, or were part of a complex rearrangement such as an unbalanced translocation, insertion, or marker chromosome were characterized as clinically significant. Alterations with unclear clinical significance were most commonly those which were not currently associated with a syndrome but which affected gene content which may have contributed to the patient\'s phenotype and those which could not be precisely refined by the BAC array. Alterations were considered to have no known clinical significance if they were small, affected minimal gene content, and/or were present in regions where common copy-number variation was known to occur in the general population. Signature\'s own Genoglyphix Chromosome Aberration Database (GCAD) was used as a reference to assist in the interpretation of each alteration. GCAD is a database of \>11,000 chromosomal abnormalities identified in \>9,500 patients out of \>40,000 patients evaluated by our laboratory and contains detailed statistics of each observed alteration (breakpoint coordinates, size, gene content, etc.) as well as clinical information pertaining to patient referral.

Fluorescence in situ Hybridization (FISH)
-----------------------------------------

When possible, all copy number alterations detected by microarray analysis were visualized by interphase and/or metaphase FISH using a BAC probe located within the region of gain or loss. FISH was performed as previously described \[[@B18]\].

Patient Clinical Testing
------------------------

To validate the custom-designed 105k oligo array compared to the whole-genome BAC array, 466 cases were run side-by-side in a platform comparison study. In each case, the clinically validated BAC array results were used for interpretation and reporting. Specimens with known chromosome abnormalities, parental specimens, and prenatal cases were excluded from the analysis.

In addition, we conducted a prospective study of 3,443 consecutive BAC microarray analyses and 3,096 consecutive oligo microarray analyses in our clinical laboratory. The array platform used for testing in each case was chosen by the referring physician at the time of sample submission to our clinical diagnostic laboratory. Cases with previously known chromosomal abnormalities, parental samples, and prenatal specimens were again excluded from the data collection.

Mosaicism Assessment
--------------------

The ability of the oligo platform to detect mosaicism was assessed on 48 patients previously known to carry mosaic abnormalities at levels as low as 5%. The alterations studied included a variety of interstitial, terminal, and whole-chromosome copy-number abnormalities, as well as marker chromosomes. The mosaic alteration in each patient was initially assessed by BAC array and the level of mosaicism determined by interphase FISH analysis when possible. In a separate experiment, mosaicism was assessed using a dilution of cells from a male with trisomy 21 with normal male control cells, as previously described \[[@B19]\]. After FISH verification of the dilutions, DNA was extracted from the diluted cells, labeled and hybridized to the custom-designed oligo array as described above.

Results
=======

Platform comparison study
-------------------------

From the 466 cases analyzed by the BAC array, using the previously described algorithm, we excluded 347 cases that only had aberrations located within regions that contained no genes and/or aberrations that had been established to be normal population variants by Signature Genomic Laboratories or identified in the Toronto Database of Genomic Variants (DGV, <http://projects.tcag.ca/variation/>). After these cases were excluded, 138 copy number alterations in 119 cases (25.5% of the original 466 cases) remained that required FISH analysis. These aberrations included subtelomeric and pericentromeric gains for which FISH was required to exclude an unbalanced translocation or a marker chromosome. After FISH was performed, 60 aberrations in 52 cases were classified as normal variants because marker chromosomes and derivative chromosomes were not identified and because these alterations were located within regions where common copy number variation is known to occur. Thus, alterations of potential clinical significance according to our algorithm were identified in 67 cases, a detection rate of 14.4%. Of these cases, 56 (12.0%) were considered to contain clinically significant copy number alterations (Table [1](#T1){ref-type="table"}), and 11 (2.4%) were considered to contain copy number variants of unclear clinical significance for which parental analyses were recommended to further clarify the abnormality (Table [2](#T2){ref-type="table"}). aCGH and FISH analysis performed on parental samples revealed that six alterations of unclear significance were inherited from a carrier parent and one was a *de novo*event in the proband. The origin of the other four unclear alterations could not be determined.

###### 

Cases with Alterations of Clinical Significance Identified by BAC and Oligo aCGH.

  Pt. \#                                                         Chr     Band           **Start pos**.   **End pos**.   Gain/Loss   Size          \# of BACs   \# of Oligos
  -------------------------------------------------------------- ------- -------------- ---------------- -------------- ----------- ------------- ------------ --------------
  **21637**                                                      chr16   p11.2          29,563,985       30,066,187     Loss        502,202       5            46
                                                                                                                                                               
  **21992**                                                      chr16   p11.2          29,563,985       30,066,187     Loss        502,202       5            46
                                                                                                                                                               
  **22013**                                                      chr16   p11.2          29,563,985       30,066,187     Loss        502,202       5            46
                                                                                                                                                               
  **21993**                                                      chr10   q25.2q25.3     114,306,207      114,925,368    Loss        619,161       3            36
                                                                                                                                                               
  **21756**                                                      chr2    q35            219,418,281      220,060,969    Loss        642,688       2            43
                                                                                                                                                               
  **22002**                                                      chr2    q37.3          239,664,393      240,400,008    Loss        735,615       3            82
                                                                                                                                                               
  **22334**                                                      chr10   q25.2q25.3     114,024,053      115,677,301    Gain        1,653,248     3            53
                                                                                                                                                               
  **21688**                                                      chr16   p13.11p12.3    15,056,257       16,742,812     Gain        1,686,555     3            61
                                                                                                                                                               
  **21667**                                                      chr17   p12            14,052,297       15,742,271     Gain        1,689,974     3            67
  **21896**                                                      chr4    q35.2          189,407,487      191,133,809    Loss        1,726,322     8            147
                                                                                                                                                               
  **22269**                                                      chr2    q12.3q13       107,945,041      109,784,684    Loss        1,839,643     6            102
                                                                                                                                                               
  **21640**                                                      chr19   q13.42         59,272,450       61,239,237     Gain        1,966,787     8            135
                                                                                                                                                               
  **22117**                                                      chr9    q33.1          118,991,777      121,063,590    Gain        2,071,813     3            67
                                                                                                                                                               
  **22066**                                                      chr8    p12p11.21      38,303,146       40,515,492     Gain        2,212,346     6            104
                                                                                                                                                               
  **21786**                                                      chr1    q21.1          144,973,942      147,421,814    Gain        2,447,872     5            63
                                                                                                                                                               
  **22237**                                                      chr1    q21.1          144,973,942      147,421,814    Gain        2,447,872     5            63
                                                                                                                                                               
  **22310**                                                      chr22   q11.21         17,299,742       19,770,655     Loss        2,470,913     13           205
                                                                                                                                                               
  **22050**                                                      chr22   q11.21         17,007,819       19,770,655     Loss        2,762,836     13           208
                                                                                                                                                               
  **21936**                                                      chr1    q21.1          144,973,942      147,966,185    Gain        2,992,243     5            65
                                                                                                                                                               
  **21719**                                                      chr2    q31.1          169,823,689      172,870,083    Loss        3,046,394     8            119
                                                                                                                                                               
  **22128**                                                      chr4    q34.3          179,065,989      182,435,119    Loss        3,369,130     3            91
                                                                                                                                                               
  **22006**                                                      chr17   p11.2          16,723,071       20,145,604     Loss        3,422,533     18           311
                                                                                                                                                               
  **22174**                                                      chr1    q41q42.12      221,260,860      224,709,317    Loss        3,448,457     9            178
                                                                                                                                                               
  **21971**                                                      chr22   q11.23q12.2    24,025,269       28,008,109     Loss        3,982,840     3            111
                                                                                                                                                               
  **22073**                                                      chr15   q11.2q13.1     21,208,177       26,194,049     Loss        4,985,872     11           281
                                                                                                                                                               
  **21687**                                                      chr16   q12.2q21       51,912,655       57,173,018     Loss        5,260,363     15           261
                                                                                                                                                               
  **21975**                                                      chr5    p15.2p14.3     13,514,464       18,988,928     Loss        5,474,464     3            122
                                                                                                                                                               
  **21555**                                                      chr7    p22.3p22.1     153,644          6,230,285      Gain        6,076,641     32           434
                                                                                                                                                               
  **21547**                                                      chr2    q24.3q31.1     168,702,606      174,842,496    Loss        6,139,890     11           226
                                                                                                                                                               
  **21755**                                                      chr11   p12p11.2       37,540,680       43,940,573     Loss        6,399,893     14           298
                                                                                                                                                               
  **21761**                                                      chr3    p14.1p12.3     70,738,914       77,275,908     Loss        6,536,994     6            151
                                                                                                                                                               
  **22151**                                                      chr15   q11.2q13.1     18,809,804       26,194,049     Gain        7,384,245     14           331
                                                                                                                                                               
  **22322**                                                      chr8    p21.3p12       22,954,212       30,630,828     Loss        7,676,616     9            224
                                                                                                                                                               
  **21889**                                                      chr2    q33.1q34       202,901,021      211,366,732    Gain        8,465,711     13           281
                                                                                                                                                               
  **21723**                                                      chr5    q23.1q23.3     121,487,477      130,306,377    Loss        8,818,900     4            204
                                                                                                                                                               
  **22337**                                                      chr1    p36.22p36.13   9,476,880        19,436,653     Loss        9,959,773     21           436
                                                                                                                                                               
  **21795**                                                      chr1    p34.2p32.3     41,201,837       55,191,500     Gain        13,989,663    17           440
                                                                                                                                                               
  **20986**                                                      chr12   p13.33p12.3    84,918           17,505,135     Gain        17,420,217    46           800
                                                                                                                                                               
  **21957**                                                      chr11   q23.3q25       116,478,434      134,419,382    Gain        17,940,948    40           784
                                                                                                                                                               
  **21596**                                                      chr1    q25.1q32.1     173,519,967      203,663,817    Gain        30,143,850    25           814
                                                                                                                                                               
  **22055**                                                      chr3    p14.1p13       71,164,161       71,958,845     Loss        794,684       3            46
                                                                                                                                                               
  **21566\***                                                    chr17   p13.2p13.1     6,081,457        6,904,679      Loss        823,222       3            14
                                                                                                                                                               
  **21558**                                                      chr22   q13.33         48,567,185       49,517,230     Loss        950,045       6            54
                                                                                                                                                               
  **21770**                                                      chr8    p23.3          202,505          1,411,517      Loss        1,209,012     5            96
                                                                                                                                                               
  **22254**                                                      chr8    p23.2          2,604,280        3,966,809      Loss        1,362,529     9            140
                                                                                                                                                               
  **21937**                                                      chr7    q11.23         72,404,049       73,771,409     Loss        1,367,360     10           158
                                                                                                                                                               
  **21710**                                                      chr15   q13.2q13.3     28,741,818       30,186,356     Loss        1,444,538     3            64
                                                                                                                                                               
  **21722**                                                      chr15   q13.2q13.3     28,741,818       30,226,376     Loss        1,484,558     3            65
                                                                                                                                                               
  **21739**                                                      chr15   q13.2q13.3     28,741,818       30,226,376     Loss        1,484,558     3            65
                                                                                                                                                               
  **21787**                                                      chr15   q13.2q13.3     28,741,818       30,226,376     Loss        1,484,558     3            65
                                                                                                                                                               
  **21897\***                                                    chr5    p15.2          8,511,592        9,888,817      Gain        1,377,225     34           29
                                                                                                                                                               
  **21884**                                                      chrX    q28            152,676,750      153,059,428    Gain        382,678       3            44
                                                                                                                                                               
  **21592**                                                      chrX    p22.33q28      701              154,888,083    Gain        154,887,382   325          6888
                                                                                                                                                               
  **22087**                                                      chrY    p11.32         262,578          57,715,879     Gain        57,453,301    49           49
                                                                                                                                                               
  **22285**                                                      chrX    p21.1          31,759,551       31,830,811     Loss        71,260        2            11
                                                                                                                                                               
  **22244**                                                      chr22   q13.33         49,342,961       49,514,486     Loss        171,525       2            56
                                                                                                                                                               
  \*additional alterations identified by oligonucleotide aCGH.                                                                                                 

###### 

Cases with Alterations of Unclear Significance Identified by BAC and Oligo aCGH.

  Pt. \#      Chr     Band     Start pos.    End pos.      Gain/Loss   Size        \# of BACs   \# of Oligos   Inheritance
  ----------- ------- -------- ------------- ------------- ----------- ----------- ------------ -------------- -------------
  **22365**   chr9    p23      9,881,385     9,984,838     Loss        103,453     2            15             Paternal
                                                                                                               
  **21702**   chr16   p12.2    21,486,897    21,641,890    Loss        154,993     2            16             Paternal
                                                                                                               
  **21883**   chr16   p12.1    21,974,396    22,338,234    Gain        363,838     3            49             Maternal
                                                                                                               
  **21860**   chr16   p12.1    21,907,270    22,338,234    Loss        430,964     3            50             Unknown
                                                                                                               
  **22009**   chr22   q11.21   19,069,125    19,770,655    Loss        701,530     4            70             Paternal
                                                                                                               
  **22102**   chr16   p13.11   14,981,044    16,166,985    Gain        1,185,941   3            60             Maternal
                                                                                                               
  **22246**   chr10   p11.22   31,591,310    32,792,762    Loss        1,201,452   2            40             Unknown
                                                                                                               
  **21893**   chrX    p11.32   45,930,652    46,382,140    Gain        451,488     3            34             Maternal
                                                                                                               
  **22273**   chrX    q28      153,355,101   154,317,591   Gain        962,490     5            46             Unknown
                                                                                                               
  **10245**   chr3    p14.1    67,727,841    69,101,769    Loss        1,373,928   2            25             Unknown
                                                                                                               
  **22348**   chr13   q22.2    74,989,699    75,378,640    Loss        388,941     3            51             De novo

Using the oligo array, we identified 1,337 copy number variations among the same 466 cases. Using the algorithm previously described, we excluded 1,172 aberrations that were located within regions that had no gene content or those that were common copy number variants. After these exclusions were made, 165 aberrations in 138 cases (29.6%) remained that required FISH analysis. After FISH analysis was performed, aberrations of potential clinical significance were identified in 73 cases, a detection rate of 15.7%. Of these, the same 56 (12.0%) cases that were identified by the BAC platform were considered to contain clinically significant alterations (Table [1](#T1){ref-type="table"}) and 17 (3.7%) were determined to contain copy number variants of unclear clinical significance.

Table [3](#T3){ref-type="table"} shows the six cases for which aberrations of unclear clinical significance were identified by the oligo array but not by the BAC array. In all six cases, the aberrations either fell within the gaps in the BAC array coverage or were only partially covered by one or more BACs. The average size of the alterations that were not detected by the BAC array was 1.12 Mb (range: 289 kb - 1.42 Mb).

###### 

Cases with Alterations of Unclear Significance Detected by Oligo Array but not Identified by BAC Array.

  Pt. \#      Chr     Band         Start pos.    End pos.      Gain/Loss   Size        \# of Oligos
  ----------- ------- ------------ ------------- ------------- ----------- ----------- --------------
  **9756**    chr2    p25.1        11,097,126    12,515,559    Loss        1,418,433   19
                                                                                       
  **9886**    chr1    q42.12       222,702,622   223,461,255   Loss        758,633     16
                                                                                       
  **10141**   chr2    q32.3q33.1   196,729,308   197,880,950   Loss        1,151,642   30
                                                                                       
  **10114**   chr15   q26.3        97,299,441    97,745,782    Gain        446,341     16
                                                                                       
  **10292**   chr7    p14.3        33,202,932    33,492,136    Loss        289,204     5
                                                                                       
  **10019**   chr2    p16.3        51,079,474    51,993,245    Gain        913,771     13

In two cases, the oligo microarray identified additional complexity that was not recognized by the BAC array. In patient 21566, the BAC array identified one interstitial deletion of 17p13.2p13.1, whereas oligo array analysis identified that deletion and an additional interstitial deletion in the same band (data not shown). In patient 21897, the BAC array identified a 6.8 Mb terminal deletion of 5p, whereas oligo array analysis identified that deletion and a 1.4 Mb duplication proximal to the deleted region (Figure [1](#F1){ref-type="fig"}).

![**Identification by oligonucleotide microarray of additional complexity missed by BAC microarray**. **(A)**BAC microarray results showing a single-copy loss of 34 BAC clones from the terminus of 5p, approximately 6.8 Mb in size (chr5: 387,034-7,150,950, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the p-arm probes to the left and q-arm probes to the right. **(B)**shows oligonucleotide microarray results of the terminal deletion shown in (A) in addition to single-copy gain of 29 probes from 5p, approximately 1.38 Mb in size (chr5: 8,511,592-9,888,817, based on UCSC 2006 hg 18 assembly). Probes are ordered as in the BAC array. Regions shaded in blue represent deletions detected by microarray, whereas duplications are shaded in pink.](1755-8166-3-11-1){#F1}

Prospective Diagnostic Comparison
---------------------------------

Of the 3,443 diagnostic specimens analyzed using our whole-genome BAC array, 605 (17.6%) had copy number alterations. Using the previously described algorithm, 365 (10.6%) had abnormalities that were classified as clinically significant, whereas 240 (6.9%) had copy number variants of unclear clinical significance.

Of the 3,096 diagnostic specimens analyzed using our whole-genome oligo array during the same time period, 698 (22.5%) had copy number alterations. Using the previously described algorithm, 477 (15.9%) of these cases were determined to contain alterations considered to be clinically significant and 221 (7.0%) were determined to contain copy number variants of unclear clinical significance (Table [4](#T4){ref-type="table"}).

###### 

Summary of the Prospective Diagnostic Comparison.

                    BAC           Oligo
  ----------------- ------------- -------------
  **Total**         3,443         3,096
                                  
  **Abnormal**      605 (17.6%)   698 (22.5%)
                                  
  **Significant**   365 (10.6%)   477 (15.4%)
                                  
  **Unclear**       240 (7.0%)    221 (7.1%)
                                  
  **Mosaic**        16 (0.5%)     12 (0.4%)

The increased number of cases with clinically significant alterations detected by the oligo array was found to be statistically significant using a Fisher\'s Exact Test (OR = 1.5359, p \< .0001). The increased number of cases with alterations of unclear significance detected by the oligo array was not statistically significant (OR = 1.0259, p = 0.8090).

Mosaicism Assessment
--------------------

All but three of the 48 previously known mosaic alterations were detected by the oligo array. FISH analysis estimated that the proportion of uncultured cells carrying the alteration was 24% in the first case, while the proportion in cultured cells was 6%. In the second case, 5% of cells were found to carry the alteration by FISH (data not shown). The proportion of cells carrying the alteration in the third case could not be determined because FISH confirmation was not possible on the sample received by our laboratory. Certain alterations, such as tetrasomy 12p, were successfully detected in proportions of cells as low as 10% by the oligo array, although this low threshold of detection was facilitated by the tetrasomic nature of the rearrangement; the 4:2 ratio of patient to control DNA in this case was more readily detected than the 3:2 ratio typically associated with duplications. Figure [2](#F2){ref-type="fig"} shows a 2.77 Mb interstitial deletion at 16q12.1 present in 23% of cultured metaphase cells that was detected by the oligo array.

![**Oligonucleotide microarray analysis of a mosaic 16q12.1 deletion (shaded blue region)**. The zoomed-in microarray plot shows a single-copy loss of 289 probes from 16q12.1, approximately 2.77 Mb in size (chr16: 46,837,260-49,605,054, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the most proximal 16q11.2 probes to the left and the most distal 16q12.2 probes to the right.](1755-8166-3-11-2){#F2}

In the dilution series of trisomy 21 cells, shifts in the aCGH data were distinguishable down to levels as low as 10%, but could only be readily detected at a level of 30% or greater (Figure [3](#F3){ref-type="fig"}). As the proportion of trisomy 21 cells was increased from 10% to 30%, the average log~2~ratio of chromosome 21 increased from 0.08 to 0.21. During the prospective diagnostic comparison, 16 cases analyzed using the BAC array contained mosaic alterations, whereas only 12 mosaic cases were identified using the oligo array (Table [5](#T5){ref-type="table"}). The increased number of mosaic abnormalities detected by the BAC array was determined to be not statistically significant (OR = 1.1999, p = 0.7066).

![**Oligonucleotide microarray analysis of artificially derived mosaic trisomy 21 samples**. **(A)**10% trisomy 21 showing a very subtle copy-number gain for all clones on chromosome 21. The profile was generated using DNA extracted from a mixture of blood which contained 10% WBCs from a trisomy 21 subject and 90% WBCs from a normal male individual. **(B)**15% trisomy 21, generated as in (A), showing a very subtle copy-number gain for all clones on chromosome 21. **(C)**20% trisomy 21, generated as in (A) showing a subtle copy-number gain for all clones on chromosome 21. **(D)**30% trisomy 21, generated as in (A), showing a clear copy-number gain for all clones on chromosome 21. The inset images to the right of each array plot show the average log~2~ratio of all probes mapping to chromosome 21, with the horizontal dotted line representing a log~2~ratio of zero and the vertical dotted line representing the centromere. A pink bar plotted above the horizontal line represents a copy-number gain of all probes on chromosome 21. To the left of each inset image is the average log~2~ratio at the specified proportion of trisomic cells.](1755-8166-3-11-3){#F3}

###### 

Mosaic Alterations Detected in the Prospective Diagnostic Comparison.

  Pt. \#      Proportion (%)   Classification
  ----------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------
  **BAC**                      
                               
  **25885**   10               45,X
                               
  **25838**   10               47,XX,i(12)(p10)
                               
  **27745**   10               46,XY,trp(12)(p13.33p10)
                               
  **26912**   18               47,XY,i(8)(p10)
                               
  **26358**   20               46,XX,dup(2)(p14p11.2)
                               
  **26880**   24               47,XX,+9
                               
  **23302**   27               47,XX,+der(9)(p21.2q11)
                               
  **23919**   46               47,XY,+der(12)(p13.33q11)
                               
  **26127**   53               46,XY,del(18)(q22.3q23)
                               
  **26750**   57               47,XY,+der(8)(p11.22q11)
                               
  **26894**   60               45,X
                               
  **24887**   70               46,XX,der(14)dup(14)(q32.13q32.2)del(14)(q32.3q32.33)
                               
  **23159**   70               47,XYY
                               
  **23155**   77               46,XX,idic(18)(q21.33)
                               
  **23215**   87               47,XX,+21
                               
  **25862**   93               48,XX,+der(13)(pterq12.12),+der(20)(p11.21q11)
                               
  **Oligo**                    
                               
  **27978**   21               48,XY,+der(13)(pterq12.11),+der(?)(?::Xp22.31-\>Xp22.31::Xp22.2-\>Xp22.12::?-\>cen-\>?)
                               
  **32047**   27               47,XXY
                               
  **32374**   27               46,XX,r(X)(p11.1q21.1)
                               
  **32875**   33               47,XY,+inv dup(22)(q11.21)
                               
  **29361**   53               47,XX,+der(11)(p11.2q11)
                               
  **31439**   63               47,XY,+der(12)(:p13.33::p13.31-\>p13.2::p11.23::p11.22-\>p11.21::?-\>12cen-\>?::p11.21-\>p11.22::p11.23::p13.2-\>::p13.31::p13.33:)
                               
  **31633**   63               48,XX,+der(4)(p13q12),+der(13)(pterq12.11)
                               
  **30028**   77               46,XY,del(7)(q22.1q22.3),del(12)(q21.31q22)
                               
  **31336**   80               46,XX,idic(X)(q21.1)
                               
  **27105**   90               47,XX,+der(13)(pterq12.12)
                               
  **29786**   90               46,X,+der(X)(p11.21q11.1)
                               
  **30218**   93               47,XY,+der(17)(p11q11.2)

Discussion
==========

BAC and oligo array platforms each have unique advantages and disadvantages in a diagnostic setting; these may include turnaround times, genomic coverage, and costs. One of the most important characteristics of each platform is the detection rate of clinically significant alterations. Our results demonstrate that our whole-genome oligo array was able to detect such alterations in 15.4% of patients tested, compared to the BAC array detection rate of 10.6%, a statistically significant difference (Fisher\'s Exact Test, p \< 0.0001). The alterations that constitute the 4.8% difference in detection rate between the BAC and oligo arrays are either too small to be detected by the BAC array but are not below the resolution of the oligo platform (Figure [4](#F4){ref-type="fig"}) or fall within gaps in the BAC array coverage (Figure [5](#F5){ref-type="fig"}). Figure [4](#F4){ref-type="fig"} shows a 44 kb deletion of 17p13.3 detected in a patient referred to our laboratory for convulsions. This deletion encompasses the first exon of *PAFAH1B1*(*LIS1*). While it is not known whether this deletion results in a null allele or simply a truncated gene product, hemizygous deletions and mutations of this gene are found in patients with isolated lissencephaly type 1 (OMIM 607432) and have been linked to epileptic seizures and convulsions \[[@B20],[@B21]\]. Although RP11-135N5 provides coverage of this region on the BAC array, FISH analysis using this clone could not confirm the deletion in any cells because of the deletion\'s small size compared to the FISH probe used. Thus, this clinically significant deletion could only have been reliably detected using the oligo platform. Although oligo-based aCGH has the power to detect alterations smaller than the size of a BAC probe, BAC-based aCGH has an advantage in that the analysis makes evident the appropriate probe to be used for FISH confirmation. In addition, this probe is usually readily available because of its inclusion on the microarray platform and will have a high rate of successful confirmation. When oligonucleotide-based aCGH is performed, BAC probes must be specifically selected for the FISH confirmation of each small abnormality that is detected. Once a probe has been selected, it must also be specially prepared or ordered before FISH can be performed. This process increases both the time it takes to perform FISH confirmation of oligo aCGH results and the cost associated with the analysis.

![**Oligonucleotide microarray characterization of an interstitial deletion at 17p13.3**. The zoomed-in microarray plot shows a single-copy loss of six probes from the short arm of chromosome 17 at 17p13.3, approximately 44.0 kb in size (chr17: 2,415,074-2,459,051, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the most distal 17p13.3 probes to the left and the most proximal 17p13.3 probes to the right. Below is a schematic of the deletion region. The deletion disrupts the *PAFAH1B1/LIS1*gene.](1755-8166-3-11-4){#F4}

![**Oligonucleotide microarray characterization of an interstitial deletion at 6q14.1**. The zoomed-in microarray plot shows a single-copy loss of 43 oligonucleotide probes from the long arm of chromosome 6 at 6q14.1, approximately 2.9 Mb in size (chr6: 79,838,518-82,730,466, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the most proximal 6q14.1 probes to the left and the most distal 6q14.1 probes to the right. Below is a schematic of the deletion region. Blue and gray boxes represent genes in the deletion region.](1755-8166-3-11-5){#F5}

Figure [5](#F5){ref-type="fig"} shows a 2.9 Mb deletion of 6q14.1 detected in a patient referred to our laboratory for developmental delay and dysmorphic features. This deletion encompasses eight genes: *PHIP*, *HMGN3*, *LCA5*, *SH3BGRL2*, *ELOVL4*, *TTK*, *BCKDHB*, two of which are known to be associated with human disease \[[@B22]-[@B24]\]. Although this 2.9 Mb deletion is likely to be clinically significant, it lies within a gap in the coverage of our BAC array and could only be detected using the oligo platform because of its more uniform backbone coverage.

The detection rate of alterations of unclear clinical significance is also a concern during the selection of a microarray platform in a clinical diagnostic setting. Our data suggest that both the oligo and BAC platforms detect similar numbers of abnormalities of unclear significance (7.0% by BAC and 7.1% by oligo), although the circumstances leading to an unclear clinical interpretation may vary between the platforms. On the BAC platform, unclear results are often associated with gaps in coverage which prevent the precise determination of the breakpoints and gene content of an abnormal region. This lack of information prohibits definitive interpretation of the clinical significance of the alteration. Figure [6](#F6){ref-type="fig"} presents a 262 kb deletion of 9q33.1 detected by BAC array in a patient referred for developmental delay, dysmorphic features, and multiple congenital anomalies. The boundaries of this alteration as defined by BAC array include only one gene, *TLR4*\[[@B25]\]. However, gaps in BAC coverage on both sides of the alteration span 4.5 Mb proximally and 4.0 Mb distally. As a result of these coverage gaps, this alteration, though estimated to be just 262 kb, may be as large as 8.7 Mb and include up to 48 additional genes. The design of BAC arrays with dense clone coverage is possible; however, probe density is limited by the availability of BAC clones and the presence of potentially interfering genomic architecture such as segmental duplications. In addition, BAC-based microarrays will not reliably detect abnormalities smaller than the size of an individual probe\--80-200 kb, on average, for BAC clones.

![**BAC microarray characterization of a 9q33.1 deletion**. The zoomed-in microarray plot shows a single-copy loss of three BAC clones from the long arm of chromosome 9 at 9q33.1, approximately 262 kb in size (chr9: 119,452,279-119,714,054 based on UCSC 2006 hg 18 assembly). The nearest distal clone on chromosome 9 that is not deleted is RP11-977E8 and is approximately 4.0 Mb away from the deleted region. The nearest proximal clone on chromosome 9 that is not deleted is RP11-999I23 and is approximately 4.4 Mb away from the deleted region. Probes are ordered on the x axis according to physical mapping positions, with proximal 9q32 clones to the left and distal 9q33.2 clones to the right. Below is a schematic of the deletion region. Vertical blue lines represent the minimum size of this alteration, which encompasses one gene, *TLR4*.](1755-8166-3-11-6){#F6}

Although gaps in coverage and limited breakpoint-resolving power are primarily a concern for BAC platforms, both oligo and BAC platforms produce results that are unclear because a lack of published evidence prevents a conclusive association between the gene content of an alteration and the clinical features of the patient from being made. Figure [7](#F7){ref-type="fig"} presents a 160 kb deletion of 4q25 detected by oligo array in a patient referred for developmental delay. Follow-up analysis performed on this patient\'s parents revealed that this alteration was *de novo*in origin. This alteration deletes two genes, *PAPSS1*and *SGMS2*. While mutations or alterations of these genes have not been associated with disease in humans, it has been shown that PAPSS1 plays a key role in post-translational modification and SGMS2 mediates the production of sphingomyelin \[[@B26],[@B27]\]. Thus, although the gene content and inheritance pattern of this deletion suggest a causative role in the patient\'s clinical features, a lack of published information linking the genes affected by this alteration with a distinct phenotype prevents a clear interpretation from being made based on only aCGH results. This type of unclear result, although more prominent with oligo platforms (4.2% by BAC vs. 7.1% by oligo), is an element of all aCGH analysis regardless of platform and accentuates the need for databases containing aCGH results in combination with phenotypic information. Although the number of characterized genetic disorders and genomic regions is rapidly increasing, the clinical consequences of alterations involving much of the genome still remain unclear.

![**Oligonucleotide microarray characterization of an interstitial deletion at 4q25**. The zoomed-in microarray plots shows a single-copy loss of 15 oligonucleotide probes from the long arm of chromosome 4 at 4q25, approximately 159.6 kb in size (chr4: 108,834,399-108,994,048, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with proximal 4q25 clones to the left and distal 4q25 clones to the right. Below is a schematic of the deletion region. The deletion disrupts the *PAPSS1*and *SGMS2*genes, represented by blue boxes.](1755-8166-3-11-7){#F7}

The increase in the number of copy number alterations identified by higher-resolution whole-genome arrays underscores the need for a variety of tools to facilitate the interpretation of array results in a clinical diagnostic setting. We propose the use of an algorithm such as the one outlined here in conjunction with databases of normal population variants, clinically significant alterations, and those of unclear significance. Although such databases can provide invaluable context for the analysis of aCGH data, care must be taken by the diagnostician when comparing their data to pre-existing databases of copy-number variations. For example, data in the DGV are pooled from a variety of sources, platforms, and populations using a variety of different controls and without independent verification, and thus may not be appropriate for comparison in all situations. Furthermore, recent evidence suggests that most data in the DGV overestimate the size of the regions involved because they are dependent primarily on BAC array data, which has a tendency to overestimate the true size of small aberrations \[[@B28]\]. Thus, the most useful CNV databases may be those generated by individual laboratories using identical reference controls and array platforms. Based on our experience, we have constructed a database of abnormal copy number aberrations identified by BAC and oligo aCGH in our laboratory and a database of copy-number variations thought to have no significance. Such databases are essential for understanding the various copy number aberrations identified by microarray analysis.

Genotype-phenotype correlations in a diagnostic setting must address a variety of factors including gene content, potential position effects, aberration size, and inheritance patterns. These factors often present conflicting evidence about the potential clinical significance of a rare alteration. For instance, the size of an abnormality is commonly used as justification for its proposed clinical consequences; however, this association is not always straightforward. High-resolution microarray analysis routinely detects abnormalities smaller than 500 kb that disrupt clinically significant genes and have clear phenotypic impact (Figure [4](#F4){ref-type="fig"}); conversely, numerous examples of common copy-number variants have been observed that are relatively large but lie in regions with sparse gene content. In addition, although it is generally assumed that *de novo*abnormalities are causative and inherited abnormalities are not, this is not always the case. There are a number of regions of the genome where both inherited and *de novo*copy number alterations have been identified, some of which result in mild phenotypes that may be inherited from parents who have a milder or subclinical, presentation. For example, deletions of distinct regions of 1q21 have been associated with both thrombocytopenia absent radius (TAR) syndrome and a variable phenotype including microcephaly/macrocephaly, developmental delay, cardiac abnormalities, and schizophrenia \[[@B29]-[@B31]\], but in many instances aberrations of these regions are inherited from phenotypically normal parents \[[@B32]\]. Another example is the 16p11.2 region associated with a range of cognitive, developmental, and speech delays, behavioral issues, and autism, deletions and duplications of which can be inherited or *de novo*\[[@B33]-[@B36]\]. In regions such as these, copy number changes may unmask recessive alleles or work in conjunction with various genetic modifiers, perhaps even other CNVs, to produce a clinical phenotype. Potentially, non-paternity may also confound genotype-phenotype correlation for copy number alterations in these complex regions of the genome. These reasons underscore the need for thorough databases of normal population variants and clinically significant alterations complete with genotype-phenotype correlations. Such databases expedite the process of determining the potential significance of copy-number alterations in a diagnostic setting; aid in the elucidation of new microdeletion/duplication syndromes and new regions of benign copy-number variation; and help reduce the burden of expensive, time-consuming, and difficult follow-up necessitated by the increased number of alterations of unclear clinical significance detected by microarray analysis.

We \[[@B19]\] and others \[[@B37]\] have shown that mosaicism can be detected at low frequencies of chromosomally abnormal cells using BAC-based aCGH; however, the ability of oligo platforms to reliably detect mosaic abnormalities has not yet been well established. Our current assessments demonstrate that aCGH using either BAC or oligo platforms can easily detect mosaicism of 30% or greater for a variety of alterations and that levels as low as 10% can be detected with both platforms under optimal conditions. In addition, our retrospective analysis showed that there is no significant difference between the two types of platforms in the number of mosaic abnormalities detected in a clinical diagnostic setting (p = 0.7066). However, BAC-based arrays may still have a greater ability to detect mosaic abnormalities present at very low levels (less than 20%), perhaps due to the routine use of dye-swap experiments which can be cost-prohibitive with oligo arrays but promote the visual identification of mosaic abnormalities. The sensitivity of the BAC array is demonstrated by the detection in three cases of abnormalities in only 10% of cells during the retrospective study, whereas the lowest level of mosaicism detected by our oligo array was 21% (Table [5](#T5){ref-type="table"}). The ability of an aCGH platform to detect mosaic abnormalities also depends largely on the effectiveness of the software used to analyze the data, as low-level mosaic alterations are difficult to identify using only visual inspection (Figure [3](#F3){ref-type="fig"}). For this reason, it is important to select analysis software which facilitates the identification of mosaic alterations.

These data suggest high-resolution oligo-based aCGH detects a higher proportion of clinically significant abnormalities than BAC-based aCGH. Our results also demonstrate the ability of microarray-based CGH to reliably produce high-yield results in a clinical setting using differing platforms, array designs, and analysis algorithms, supporting the validity of array CGH as a first-tier diagnostic screening tool \[[@B38]\]. Finally, the prevalence of copy number variants of unclear clinical significance detected on both platforms underscores the need for the development of readily accessible diagnostic tools in the form of databases of documented chromosome abnormalities to aid in the interpretation of microarray data.
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